Page 10 - Unity Biotechnology Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Unity biotechnology inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Unity Biotechnology Inc Today - Breaking & Trending Today

Pets at Home Group Plc (LON:PETS) Receives GBX 365 Average PT from Brokerages

Unity Biotechnology (NASDAQ:UBX – Get Rating) had its price objective reduced by Mizuho from $12.00 to $6.00 in a research report released on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. A number of other equities analysts also recently issued reports on the company. HC Wainwright reissued a buy […] ....

Judith Campisi , Nathaniel Eames David , Jan Van Deursen , Unity Biotechnology Inc , Dimensional Fund Advisors , Capital Investment Advisors , Arete Wealth Advisors , Schonfeld Strategic Advisors , Unity Biotechnology , Get Rating , Wealth Advisors , Street Group , Strategic Advisors , Daohong Zhou , South San Francisco , Unity Biotechnology Daily , Nasdaq Ubx , Lower Price Target ,

Mizuho Trims Unity Biotechnology (NASDAQ:UBX) Target Price to $6.00

Unity Biotechnology (NASDAQ:UBX – Get Rating) had its target price decreased by Mizuho from $12.00 to $6.00 in a report published on Tuesday morning, The Fly reports. Mizuho currently has a buy rating on the stock. UBX has been the topic of a number of other reports. Wedbush reiterated an outperform rating and set a […] ....

Jan Van Deursen , Judith Campisi , Nathaniel Eames David , Unity Biotechnology Company Profile , Capital Management , Unity Biotechnology Inc , Venture Management , Vanguard Group Inc , Unity Biotechnology , Get Rating , Asset Management , Daohong Zhou , South San Francisco , Unity Biotechnology Daily , Nasdaq Ubx , Lower Price Target ,

HC Wainwright Reiterates "Buy" Rating for Unity Biotechnology (NASDAQ:UBX)

Unity Biotechnology (NASDAQ:UBX – Get Rating)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 488.24% from the stock’s current price. Other […] ....

Judith Campisi , Nathaniel Eames David , Jan Van Deursen , Renaissance Technologies , Virtu Financial , Unity Biotechnology Inc , Acadian Asset Management , Unity Biotechnology , Get Rating , Asset Management , Street Corp , Exoduspoint Capital Management , Daohong Zhou , South San Francisco , Unity Biotechnology Daily , Nasdaq Ubx , Reiterated Rating , Hc Wainwright ,